Blue Ocean invests in Abionic

NE Holding, Drexel Morgan and several business angels also took part in the funding round. The proceeds will be used to bring its allergy diagnostic platform to the European market in 2015. It will also be specifically used to obtain the American certification FDA 510k.

MedHoldings is a Swiss private equity and venture capital company, investing in medtech companies in Switzerland, Europe and emerging markets.

Geneva-based Blue Ocean Ventures invests in high-tech companies in Switzerland and surrounding countries. Its fund receives commitments from high-net-worth individuals and family offices.

Previous funding
Abionic raised a CHF 3.5m series-A funding round in 2012. The capital was used to complete development of the abioScope and to obtain the CE mark for its product. Polytech Ventures previously invested in the company.

Together with a CHF 500,000 loan in 2013 from the Foundation for the Innovation of Technology (FIT), the company has so far raised a total of CHF 7.8m.

Company
Abionic span out of the Swiss Federal Institute of Technology in Lausanne in September 2010. It uses medical technology, biotechnology and nanotechnology, based on nanofluidics, to provide patients with personal allergy profiles.

It is able to provide results from a single drop of blood within 20 minutes using its portable biomedical devices, the abioDisc and the abioScope. The disc uses nanofluidic biosensor technologies and can be used to detect allergies to pollen, food and pets among others. The abioScope reads the abioDisc biosensors and provides the diagnostic result within 20 minutes.

People
Walid Hanna is managing partner and director at MedHoldings. Nicolas Durand is CEO of Abionic.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Switzerland